Biosimilars Global Market Report 2026

Biosimilars are medications derived from living organisms, produced using various methods and slightly different materials. Their complexity, high production costs, and large molecular structures make them fundamentally different from generic drugs.

The main types of biosimilars include human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys that stimulates the production and maintenance of red blood cells. Biosimilar products include recombinant non-glycosylated proteins and recombinant glycosylated proteins, used to treat oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other medical conditions.

Tariffs have influenced the biosimilars market by increasing the cost of raw materials, bioprocessing equipment, and active pharmaceutical ingredients, leading to higher production costs and supply chain disruptions. The market segments most affected include monoclonal antibodies and insulin biosimilars, particularly in regions like north america and europe, which rely on imported biologics components. While tariffs have posed challenges, they have also encouraged domestic manufacturing and local production strategies, potentially strengthening regional supply resilience and fostering innovation in cost-effective biosimilar development.

The biosimilars market research report is one of a series of new reports from The Business Research Company that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biosimilars market size has grown rapidly in recent years. It will grow from $21.85 billion in 2025 to $25.53 billion in 2026 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to rising prevalence of chronic and autoimmune diseases, high cost of originator biologics, increasing demand for cost-effective therapies, advancements in biopharmaceutical R&D, growing healthcare infrastructure in emerging economies.

The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $48.52 billion in 2030 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to patent expirations of blockbuster biologics, increasing adoption of biosimilars in oncology and autoimmune therapy, government incentives and supportive policies, expansion of manufacturing capabilities in asia-pacific, growing partnerships between biopharma companies and contract manufacturing organizations. Major trends in the forecast period include personalized biosimilar development, cost-effective biologics manufacturing, regulatory harmonization and compliance, expansion of emerging markets for biosimilars, strategic collaborations and partnerships.

The rising healthcare expenditures are anticipated to drive the growth of the biosimilars market in the coming years. Healthcare expenditures encompass the total spending on healthcare goods and services within a population or healthcare system. The biosimilars market contributes to reducing healthcare costs by providing more affordable alternatives to expensive biologic drugs, thereby lowering treatment expenses for patients and healthcare systems. For example, in March 2024, according to the Health Foundation, a UK-based independent charity and think tank, total health expenditures in England for 2022/23 reached £182 billion ($196.78 billion). While planned health spending is projected to rise to £192 billion ($207.59 billion) in 2024/25, inflation will result in only a modest real-term increase of 0.6% compared to the 2023/24 fiscal year. Consequently, rising healthcare expenditures are supporting the expansion of the biosimilars market.

Key players in the biosimilars market are focusing on developing innovative products to secure a competitive advantage. FYLNETRA is a leukocyte growth factor indicated to reduce the risk of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer therapies associated with a clinically significant incidence of febrile neutropenia. For instance, in May 2023, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, commercially launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar referencing Neulasta, in a pre-filled single-dose syringe. FYLNETRA treats neutropenia, a condition of low neutrophils-white blood cells essential for fighting infection-commonly observed in chemotherapy patients.

In January 2024, Sandoz, a Switzerland-based pharmaceutical company, acquired the CIMERLI (ranibizumab) biosimilar business from Coherus BioSciences for an undisclosed sum. Through this acquisition, Sandoz aims to enhance its ophthalmic biosimilar portfolio and expand its commercial footprint in the U.S. market. Coherus BioSciences is a US-based biotechnology company engaged in developing and marketing biosimilars and innovative biologic therapies.

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilars Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Monoclonal Antibodies; Insulin; Erythropoietin; Granulocyte-Colony Stimulating Factor; Other Hormones
• 2) By Protein Type: Recombinant Non-glycosylated Proteins; Recombinant Glycosylated Proteins
• 3) By Application: Oncology; Chronic And Autoimmune Diseases; Growth Hormone Deficiency; Infectious Diseases; Other Applications
• Subsegments:
• 1) By Monoclonal Antibodies: IgG Biosimilars; Non-IgG Biosimilars
• 2) By Insulin: Rapid-Acting Insulin Biosimilars; Long-Acting Insulin Biosimilars; Premixed Insulin Biosimilars
• 3) By Erythropoietin: Epoetin Alfa Biosimilars; Darbepoetin Alfa Biosimilars
• 4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars; Pegfilgrastim Biosimilars
• 5) By Other Hormones: Growth Hormones; Hormonal Replacement Therapy Biosimilars
• Companies Mentioned: Amgen; Novartis AG; Samsung Bioepis Co. Ltd.; Viatris; Celltrion Inc.; Coherus Biosciences; Eli Lilly and Company; Dr. Reddy's Laboratories; Roche India Pvt Ltd; Abbott India Limited; Wuxi Biologics; Shanghai Henlius Biotech; Innovent Biologics; Hisun Pharma; 3SBio; Beijing ShuangLu Pharmaceuticals; Qilu Pharmaceutical; Kyowa Hakko Kirin; Takeda; Mitsubishi Tanabe; AGC Biologics; Bio-Thera; Sandoz Pty Ltd; Apotex Pty Ltd; Cadila Pharmaceuticals; BiosanaPharma; GlaxoSmithKline; AstraZeneca; Bayer; Merck; Boehringer Ingelheim; Sanofi; Fresenius Kabi; Napp Pharmaceuticals; Mundipharma Deutschland GmbH & Co. KG; Geropharm; Valenta; NovaMedica; SynBio; Rani Therapeutics; Johnson & Johnson; Biogen Inc.; Ache; Eurofarma; Teva Pharmaceuticals; Oramed Pharmaceuticals; Entera Bio; Julphar; Hikma Pharmaceuticals; BIOPHARMA-MEA; NeoTX; AID Genomics Limited; Altis Biologics; Cipla Medpro South Africa; Next Biosciences; Viome; Inqaba Biotechnical Industries (Pty)
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.